In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will be enrolled with the determined monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 might be given as "include-on" therapy. In Section C, individuals https://abbv-744clinicaltrialphas35689.ltfblog.com/31199580/5-simple-statements-about-abbv-744-clinical-trial-phase-1-results-explained